Dernières nouvelles pour  (OTC:MROFS) Stock

<p><a href="https://www.minneapolisfed.org/speeches/2025/neel-kashkari-qa-at-the-us-chamber-of-commerce-global-summit">https://www.minneapolisfed.org/speeches/2025/neel-kashkari-qa-at-the-us-chamber-of-commerce-global-summit</a></p>


Macro Economic Events

News

Politics

Economics

Federal Reserve

General

Fed's Kashkari Says Bond Yield Up And Dollar Down Indicates Some Reassessment Of Where Global Investors Want To Invest; Says All Of This Can Change Quickly, With Resolution Of Trade Uncertainty

<p><i><strong>Strategic Growth Fuels American Rebel Beer as it Reaches 10 States with Several More to be Announced Soon</strong></i></p>
<p><strong>Nashville, TN, April 22, 2025 (GLOBE NEWSWIRE) -- </strong>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) ("American Rebel" or the "Company"), creator of American Rebel Beer (<a href="https://www.globenewswire.com/Tracker?data=FJwILhs6nq8i5fNesrrragRjRxOXj5foB4S46nfzJXOSkcGp1llMj3wc5OXFjoLeu5_MTEq_AXokgr4DjIKpM4uSzeZGABjJ77Pt4B3gvUHTBhYb3QJK8RQ6ZL8fWjU8"><strong>americanrebelbeer.com</strong></a>) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (<a href="https://www.globenewswire.com/Tracker?data=FJwILhs6nq8i5fNesrrrapRAH7Fg-4-XABl_UIEA9pBM5bBKurHZAqcOkc2tYzQWjqgwmEzu3Ld0sJu1BJnkGLgtzxP7kwaPYiZV0rBfmWY="><strong>americanrebel.com</strong></a>), proudly announces its strategic expansion into North Carolina through a distribution agreement with Adams Beverages (<a href="https://www.globenewswire.com/Tracker?data=Tpremu-2TyRrHj0g97bRX74B_Yrz5f5YdhHrwLBq_NqfZuqGau8QShwqpgSWDQqX5Ye_TmFmI3N2066JBcuB3w==">adamsbev.com</a>). This move is a significant milestone in the Company's broader Southeast growth strategy.</p>


AREB

American Rebel Holdings Announces Strategic Expansion Into North Carolina Through Distribution Agreement With Adams Beverages

<p>Barclays  analyst Brandt Montour   maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Equal-Weight and lowers the price target from $151 to $122.</p>


Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Hyatt Hotels, Lowers Price Target to $122

WIIM

ADNT

AENT

ALUR

APTV

ATAT

BABA

BKNG

BROS

BYON

CANG

CAVA

CHWY

CLEU

COLA

CROX

DECK

DKNG

DOGZ

ELYS

EVGO

EXPE

FEDU

FIVE

FNKO

GENI

GOLF

GROV

HLLY

HSAI

HTHT

IRBT

KAVL

LAUR

LULU

MULN

PENN

PSNYW

RVLV

SBET

SPWH

STLA

TCOM

TSCO

ULTA

WKSP

WRBY

Select Sector SPDR-Consumer Discretionary

XPOF

YUMC

Shares of companies in the broader consumer discretionary sector are trading higher amid Treasury Secretary Scott Bessent's remarks about trade de-escalation with China, which may relieve potential cost pressures for the consumer and lead to an uptick in spending.

<p>Barclays  analyst Brandt Montour   maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Overweight and lowers the price target from $287 to $233.</p>


Barclays Maintains Overweight on Hilton Worldwide Holdings, Lowers Price Target to $233

<p>Barclays  analyst Brandt Montour   maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Overweight and lowers the price target from $116 to $99.</p>


WYNN

Barclays Maintains Overweight on Wynn Resorts, Lowers Price Target to $99

<p><a href="https://www.minneapolisfed.org/speeches/2025/neel-kashkari-qa-at-the-us-chamber-of-commerce-global-summit" title="https://www.minneapolisfed.org/speeches/2025/neel-kashkari-qa-at-the-us-chamber-of-commerce-global-summit">https://www.minneapolisfed.org/speeches/2025/neel-kashkari-qa-at-the-us-chamber-of-commerce-global-summit</a></p>


Fed's Kashkari says Logical That Tariff Leads To One-Time Increase In Prices, But Backdrop Of High Inflation Runs Risk Of Un-Anchoring Inflation Expectations; Can't Allow Inflation Expectations To Get Unanchored; So Far Long-Run Inflation Expectations Have Not Moved Much, Fed's Job To Make Sure They Don't

Fed's Kashkari Says Independent Monetary Policy Leads To Better Economic Outcomes, Is Foundational; Notes That His Own Change From Dove To Hawk To Current Moderate Came From Analysis Of Data; Tariffs Are Somewhat Inflationary, Tariffs Also Slow Growth; Fed's One Tool Is In Tension; Too Soon To Judge Path Of Interest Rates

<p><strong>CoreWeave Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) stock surged Tuesday after several Wall Street firms initiated coverage with an <a target="_blank" href="https://www.benzinga.com/quote/CRWV/analyst-ratings" rel="noreferrer noopener">Outperform or Buy rating</a>.</p>
<ul>
<li>BofA Securities analyst Brad Sills initiated coverage on Coreweave with a Buy and a price target of $42.</li>
<li>Needham analyst Mike Cikos initiated coverage on Coreweave with a Buy and a price target of $55.</li>
</ul>
<p><strong>Also Read: <a href="https://www.benzinga.com/25/04/44927300/this-nvidia-backed-ai-upstart-boasts-extremely-rapid-revenue-growth-analyst-initiates-overweight" target="_blank" rel="noreferrer noopener">Nvidia-Backed AI Startup Boasts &#8216;Extremely Rapid Revenue Growth&#8217; &#8211; JPMorgan Initiates With Overweight</a></strong></p>
<p><strong>Bank of America Securities:</strong> Sills noted that CoreWeave is well positioned to capture a share of the $79 billion AI IaaS (infrastructure as a service) market, given its rapid GPU deployment cycle, proprietary software optimized for AI workloads, and strategic relations with top-tiered AI-native companies such as <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), <strong>Microsoft Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), <strong>Meta Platforms Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and <strong>OpenAI</strong>.</p>
<p>The analyst&#8217;s calls with customers validated CoreWeave as a best-of-breed provider driven by its accelerated GPU deployment cycle, lower failure rates, increase in GPU utilization rate backed by its proprietary software, and access to power and data center technology.</p>
<p>Sills noted that these advantages are sustainable in the near term, at a time when demand for GPUs is accelerating. Moreover, CoreWeave&#8217;s proprietary software automates provisioning, load balancing, and observability. Each of these services addresses a separate software category. The ability to sustain a long-term advantage will depend on further developing these services, which could represent new software revenue over time.</p>
<p>Sills projected first-quarter revenue of $849 million and EPS loss of 12 cents.</p>
<p><strong>Needham:</strong> Cikos noted that the company&#8217;s first-mover advantage and strong execution in a supply-constrained GPU and Power market could drive stronger-than-expected growth as management accelerates economies of scale while lowering the cost of capital.</p>
<p>CoreWeave has generated significant revenue growth since launching the CoreWeave Cloud Platform in calendar 2020. It led to $1.9 billion in revenue in calendar 2024. Cikos attributed the company&#8217;s success to the positive supply-demand backdrop. AI demand has far outstripped supply, leading to long wait times for GPUs and Power. </p>
<p>CoreWeave boasts a first-mover advantage and a noteworthy relationship with <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), the analyst added.</p>
<p>The company has also done an impressive job delivering GPUs and data center capacity in a constrained Power market.</p>
<p>Surging demand for AI caught supply chains and underlying infrastructure providers off guard for both GPUs and Power, where Cikos anticipate AI demand to outpace supply for the next 5-plus years.</p>
<p>The CoreWeave model is highly accretive, with a Cash Payback Period of ~2.5 years on investments in GPUs and other Property and equipment, lower than the company&#8217;s weighted-average contract duration of ~4 years.</p>
<p>Cikos projected first-quarter revenue of $854 million and adjusted EPS loss of 19 cents.</p>
<p><strong>Price Action:</strong> CoreWeave stock is up 8.75% at $38.52 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44720941/terawulf-price-forecast-cut-as-analyst-cites-tough-bitcoin-economics-doubts-over-ai-growth-plans" target="_blank" rel="noreferrer noopener">TeraWulf Price Forecast Cut As Analyst Cites Tough Bitcoin Economics, Doubts Over AI Growth Plans</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Initiation

Trading Ideas

CRWV

MSFT

NVDA

CoreWeave Garners Praise Due To AI Growth, Nvidia Partnership

<p>Barclays  analyst Brandt Montour   maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Overweight and lowers the price target from $121 to $100.</p>


Barclays Maintains Overweight on Wyndham Hotels & Resorts, Lowers Price Target to $100

<p>TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-23. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that TFI International will report an <strong>earnings per share</strong> (EPS) of $1.02.</p>
<p>Anticipation surrounds TFI International's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.39, leading to a 20.48% drop in the share price on the subsequent day.</p>
<p>Here's a look at TFI International's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.58</td>
<td>1.78</td>
<td>1.61</td>
<td>1.36</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.19</td>
<td>1.60</td>
<td>1.71</td>
<td>1.24</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-20.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344999_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of TFI International were trading at $76.91 as of April 21. Over the last 52-week period, shares are down 44.6%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TFII/earnings"><strong>To track all earnings releases for TFI International visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

TFII

A Look at TFI International's Upcoming Earnings Report

<p>First American Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-23. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that First American Financial will report an <strong>earnings per share</strong> (EPS) of $0.82.</p>
<p>Anticipation surrounds First American Financial's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.26, leading to a 0.49% increase in the share price the following trading session.</p>
<p>Here's a look at First American Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.09</td>
<td>1.14</td>
<td>1.16</td>
<td>0.59</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.35</td>
<td>1.34</td>
<td>1.27</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>0.0%</td>
<td>1.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344992_0.png" alt="eps graph" /></p>
<h3>Performance of First American Financial Shares</h3>
<p>Shares of First American Financial were trading at $57.02 as of April 21. Over the last 52-week period, shares are up 0.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FAF/earnings"><strong>To track all earnings releases for First American Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at First American Financial's Future Earnings

<p>Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Moelis to report an <strong>earnings per share</strong> (EPS) of $0.49.</p>
<p>The market awaits Moelis's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.69, leading to a 1.91% increase in the share price on the subsequent day.</p>
<p>Here's a look at Moelis's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.49</td>
<td>0.21</td>
<td>0.10</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.18</td>
<td>0.22</td>
<td>0.18</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344983_0.png" alt="eps graph" /></p>
<h3>Tracking Moelis's Stock Performance</h3>
<p>Shares of Moelis were trading at $49.64 as of April 21. Over the last 52-week period, shares are down 4.87%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MC/earnings"><strong>To track all earnings releases for Moelis visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: Moelis's Earnings Preview

<p>QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect QuantumScape to report an <strong>earnings per share</strong> (EPS) of $-0.19.</p>
<p>The market awaits QuantumScape's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 7.04% increase in the share price the following trading session.</p>
<p>Here's a look at QuantumScape's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.21</td>
<td>-0.21</td>
<td>-0.22</td>
<td>-0.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.22</td>
<td>-0.23</td>
<td>-0.25</td>
<td>-0.24</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>25.0%</td>
<td>-8.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344974_0.png" alt="eps graph" /></p>
<h3>Performance of QuantumScape Shares</h3>
<p>Shares of QuantumScape were trading at $3.8 as of April 21. Over the last 52-week period, shares are down 29.47%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/QS/earnings"><strong>To track all earnings releases for QuantumScape visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring QuantumScape's Earnings Expectations

<p>Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Robert Half to report an <strong>earnings per share</strong> (EPS) of $0.37.</p>
<p>The market awaits Robert Half's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 6.59% drop in the share price the following trading session.</p>
<p>Here's a look at Robert Half's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.55</td>
<td>0.62</td>
<td>0.71</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.53</td>
<td>0.64</td>
<td>0.66</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>3.0%</td>
<td>-8.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344964_0.png" alt="eps graph" /></p>
<h3>Market Performance of Robert Half's Stock</h3>
<p>Shares of Robert Half were trading at $45.13 as of April 21. Over the last 52-week period, shares are down 36.38%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RHI/earnings"><strong>To track all earnings releases for Robert Half visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What to Expect from Robert Half's Earnings

<p>Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Stifel Financial to report an <strong>earnings per share</strong> (EPS) of $1.64.</p>
<p>Stifel Financial bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.25, which was followed by a 0.08% increase in the share price the next day.</p>
<p>Here's a look at Stifel Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.98</td>
<td>1.6</td>
<td>1.54</td>
<td>1.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.23</td>
<td>1.5</td>
<td>1.60</td>
<td>1.49</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>3.0%</td>
<td>2.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344955_0.png" alt="eps graph" /></p>
<h3>Performance of Stifel Financial Shares</h3>
<p>Shares of Stifel Financial were trading at $83.06 as of April 21. Over the last 52-week period, shares are up 8.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SF/earnings"><strong>To track all earnings releases for Stifel Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Stifel Financial's Earnings

<p><strong>Viking Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-23. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Viking Therapeutics will report an <strong>earnings per share</strong> (EPS) of $-0.32. </p>
<p>Investors in Viking Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.05, leading to a 6.09% drop in the share price on the subsequent day.</p>
<p>Here's a look at Viking Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.27</td>
<td>-0.25</td>
<td>-0.27</td>
<td>-0.28</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.32</td>
<td>-0.22</td>
<td>-0.20</td>
<td>-0.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>21.0%</td>
<td>28.000000000000004%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344947_0.png" alt="eps graph" /></p>
<h3>Viking Therapeutics Share Price Analysis</h3>
<p>Shares of Viking Therapeutics were trading at $23.72 as of April 21. Over the last 52-week period, shares are down 61.43%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VKTX/earnings"><strong>To track all earnings releases for Viking Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VKTX

Earnings Preview For Viking Therapeutics

<p>Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Knight-Swift to report an <strong>earnings per share</strong> (EPS) of $0.24.</p>
<p>Investors in Knight-Swift are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.03 in the last quarter, leading to a 4.71% increase in the share price on the following day.</p>
<p>Here's a look at Knight-Swift's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.33</td>
<td>0.32</td>
<td>0.28</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.34</td>
<td>0.24</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344938_0.png" alt="eps graph" /></p>
<h3>Market Performance of Knight-Swift's Stock</h3>
<p>Shares of Knight-Swift were trading at $38.62 as of April 21. Over the last 52-week period, shares are down 19.5%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Knight-Swift</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Knight-Swift.</p>
<p>Analysts have given Knight-Swift a total of 11 ratings, with the consensus rating being Buy. The average one-year price target is $54.18, indicating a potential 40.29% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Ryder System, Landstar System and Schneider National, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Ryder System, with an average 1-year price target of $174.0, suggesting a potential 350.54% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Landstar System, with an average 1-year price target of $150.0, suggesting a potential 288.4% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Schneider National, with an average 1-year price target of $27.67, suggesting a potential 28.35% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Ryder System, Landstar System and Schneider National, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knight-Swift</td>
<td>Buy</td>
<td>-3.50%</td>
<td>$269.94M</td>
<td>0.98%</td>
</tr>
<tr>
<td>Ryder System</td>
<td>Neutral</td>
<td>5.32%</td>
<td>$659M</td>
<td>4.37%</td>
</tr>
<tr>
<td>Landstar System</td>
<td>Neutral</td>
<td>0.41%</td>
<td>$153.79M</td>
<td>4.65%</td>
</tr>
<tr>
<td>Schneider National</td>
<td>Neutral</td>
<td>-2.38%</td>
<td>$128M</td>
<td>1.09%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Knight-Swift ranks at the top for Gross Profit and Return on Equity among its peers. However, it ranks at the bottom for Revenue Growth. Overall, Knight-Swift's performance is strong in terms of profitability metrics but lags behind in revenue growth compared to its peers.</p>
<h3>Unveiling the Story Behind Knight-Swift</h3>
<p>Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.</p>
<h3>Knight-Swift: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Challenges:</strong> Knight-Swift's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-3.5%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Knight-Swift's net margin is impressive, surpassing industry averages. With a net margin of <strong>3.73%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Knight-Swift's ROE excels beyond industry benchmarks, reaching <strong>0.98%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.54%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Knight-Swift's debt-to-equity ratio is below the industry average. With a ratio of <b>0.46</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/KNX/earnings"><strong>To track all earnings releases for Knight-Swift visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Knight-Swift's Future Earnings

BP shares are trading higher following a report suggesting Elliott Management increased its stake and is aiming for the company to improve its free cash flow.

<p>Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 15 unusual trades.</p>
<p>Delving into the details, we found 46% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $438,251, and 10 were calls, valued at $746,764.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Novo Nordisk during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $35.0 to $100.0 over the preceding 30 days.</p>
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745344931_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$21.15</td>
<td>$20.15</td>
<td>$21.15</td>
<td>$80.00</td>
<td>$296.0K</td>
<td>3.8K</td>
<td align="right">10</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$30.75</td>
<td>$27.1</td>
<td>$29.0</td>
<td>$35.00</td>
<td>$145.0K</td>
<td>135</td>
<td align="right">0</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.7</td>
<td>$27.4</td>
<td>$27.4</td>
<td>$35.00</td>
<td>$137.0K</td>
<td>45</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.85</td>
<td>$7.75</td>
<td>$7.8</td>
<td>$55.00</td>
<td>$114.6K</td>
<td>330</td>
<td align="right">155</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$7.9</td>
<td>$7.7</td>
<td>$7.8</td>
<td>$55.00</td>
<td>$78.0K</td>
<td>330</td>
<td align="right">155</td>
</tr>
</tbody>
</table>
</p>
<h3>About Novo Nordisk</h3>
<p>With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.</p>
<p>In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Novo Nordisk</h3>
<ul>
<li>With a trading volume of 8,386,138, the price of NVO is up by 1.78%, reaching $59.37.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
<h3>What The Experts Say On Novo Nordisk</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $64.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from BMO Capital has revised its rating downward to Market Perform, adjusting the price target to $64. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Novo Nordisk's Options Frenzy: What You Need to Know

Liability Co Int Ser Shares Of Beneficial Interest

Comments

Actualités

Dernières nouvelles pour (OTC:MROFS) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL